Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Link opens in a new tab
Search content at UTMB Health Research Expert Profiles
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Empagliflozin in heart failure with a preserved ejection fraction
EMPEROR-Preserved Trial Investigators
Cardiovascular Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
3852
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Empagliflozin in heart failure with a preserved ejection fraction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Cardiovascular Hospitalizations
22%
Cardiovascular Mortality
22%
Combined Risk
11%
Confidence Interval
22%
Diabetes
11%
Double-blind Trial
11%
Ejection Fraction
11%
Empagliflozin
100%
Hazard Ratio
22%
Heart Failure
11%
Heart Failure Hospitalization
55%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Hospitalization Risk
22%
Hypotension
11%
Low Risk
11%
Number of Hospitalization
11%
Once-daily
11%
Patients with Diabetes
11%
Patients with Heart Failure
33%
Placebo
22%
Placebo Groups
22%
Preserved Ejection Fraction
22%
Reduced Ejection Fraction
11%
Reproductive Tract Infections
11%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
11%
Urinary Tract Infection
11%
Without Diabetes
11%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Cotransporter
10%
Empagliflozin
100%
Fenyramidol
10%
Genital Tract Infection
10%
Hypotension
10%
Placebo
40%
Urinary Tract Infection
10%